Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aciphex

This article was originally published in The Tan Sheet

Executive Summary

Eisai/Janssen will market the new prescription proton pump inhibitor Aciphex (rabeprazole), which labeling compares to AstraZeneca's Prilosec (omeprazole). The drug, approved Aug. 19, is the third PPI indicated for gastroesophageal reflux disease. An advantage for Aciphex may be its adverse events profile, which shows that only headache (2.4% incidence) occurs at a rate greater than 1% in an analysis of 2,900 patients. As such, Aciphex could have an advantage in any attempt to become an OTC drug. AstraZeneca has a deal with Procter & Gamble for an OTC version of Prilosec
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS090237

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel